Leadership Team

A novel approach to target inflammatory diseases

Dr. Sven Zimmermann

Chief Executive Officer

Senior executive with broad experience in strategic development of advanced clinical stage biotech companies.

• CFO at MetrioPharm (2019-2021)

• CFO at Novimmune (2016-2019)

• CFO at Auris Medical (2014-2016)

• CFO at PregLem (2008-2014)

• Analyst at UBS (2001-2008)

Dr. Jean-Jacques Garaud

Cofounder and Executive Vice-President, Head of Scientific and Medical Affairs

Senior executive with broad and deep experience in R&D in the pharmaceutical industry

• Co-founder and CEO of Inotrem from 2014 to April 2021

• Head of Pharma Research and Early Development at Roche (2010 to 2012)

• Head of Development and Chief Medical Officer at Roche (2007 to 2010)

• Non-Executive Director Enyo, Lyon

Martin Koch

Chief Operating Officer

Senior executive with international experience in finance and operational functions.

• CFO of Genticel, a listed French biotech (2007 – 2017)

• Sales Director, Oncology Cephalon Pharma France (2006 – 2007)

• Controlling and Finance Director functions at Elan & Zeneus Pharma UK (2001 – 2005)

Dr. Marc Derive

Cofounder and Chief Scientific Officer

Senior executive with solid scientific background. Expert in TREM-1 biology. Experience in business-oriented drug discovery and innovation.

• Led the discovery and early development of TREM-1 inhibitor drug candidates

•  Built and manage Inotrem broad and solid patents portfolio (9 patents)

• Creation of INOTREM (2013)

Dr. Margarita Salcedo Magguilli

Chief Development Officer

Senior executive with broad international experience in early drug development.

• Director of Translational Research at the Oncology R&D Unit, Servier International Research Institute

• Director Translational Medicine, LFB biotechnologies

Dr. Simon Lambden

Head of Medical Sciences

Senior executive with strong expertise spanning discovery science, therapeutics development, and early and late-stage clinical trials

• Extensive clinical and translational pathway experience as an attending physician and academic in intensive care medicine and anesthesia at Cambridge University

• Track record of success in leading diverse teams and providers in delivering world-class research translation

• Consultant in Intensive Care Medicine; Cambridge University NHS trust

• Research Associate; University of Cambridge

Delphine Joyeux, PharmD.

Director of Regulatory Affairs and Quality Assurance

Senior executive with established leadership experience in worldwide Regulatory Affairs and Product Development.

• Head of Regulatory Affairs – AB Science
• Chief Development Officer, Tridek One
• Chief Operating Officer, Minka Therapeutics
• Regulatory Affairs Director, BioAlliance Pharma
• Manager, Worldwide Regulatory Affairs, Pfizer Inc